key: cord-0889530-9q63jhmy authors: Hoffmann, Marc S; Ganguly, Siddhartha title: Delayed COVID-19 Respiratory Failure in Lymphoma Patients on Rituximab-based Chemoimmunotherapy date: 2021-02-27 journal: Clin Lymphoma Myeloma Leuk DOI: 10.1016/j.clml.2021.02.009 sha: 71115c722a6256bc3e1798bedd712126e05c0691 doc_id: 889530 cord_uid: 9q63jhmy nan Reports of prolonged COVID-19 viral shedding in immunosuppressed patients with hematologic malignancies (1) and subsequent reactivation after receipt of rituximab-containing chemotherapy (2) have been not only sobering but also regrettably reflective of our institutional experience. Herein we report institutional experience with three patients with diffuse large B-cell lymphoma (DLBCL) who, differing from the report above, were identified to have COVID-19 during routine asymptomatic screening tests obtained prior to chemotherapy. All patients were appropriately quarantined and subsequently treated with rituximab containing chemoimmunotherapy with delayed onset of symptoms from COVID-19, severe infection, and poor outcomes. Similar to many centers, we have been universally testing asymptomatic patients prior to giving cytotoxic chemotherapy. In each case presented patients were identified during asymptomatic screening tests prior to administration of chemotherapy. Pursuant to initial American Society of Clinical Oncology (ASCO) guidelines for cancer care during COVID-19 (2) our current algorithm suggests a 14-day quarantine after a positive test and then reconsideration regarding resumption of therapy. Due to immune suppression in cancer patients on active therapy, we did not elect to decrease the quarantine period to 10 days with the August 3 Centers for Disease Control (CDC) update (3) . In each of these cases, the patients were either symptomatic from the DLBCL or at risk of a treatment failure for high risk disease and it was felt that continuing chemoimmunotherapy was in their best interest. In each case, after hospitalization a comprehensive evaluation with both infectious disease and pulmonary consultants was performed. All patients had CT scans of the chest that revealed multifocal infiltrates and early development of fibrosis consistent with coronavirus pneumonia and its pulmonary sequelae. Patients 1 and 2 underwent a bronchoscopy with bronchioalveolar lavage (BAL) and patient 3 had conventional sputum analysis. Bronchoscopy for patient 3 was deferred due to development of acute stroke on day 2 of hospitalization. Extensive evaluation for fungal, bacterial, and other viral pathogens was performed and, in all cases, was negative. In each case, the respiratory syndrome was felt to be related to progressive lung injury due to coronavirus-19. The underlying lymphoma histologies, treatment plans, and characteristics regarding their infection history are detailed below in table 1. Patient 1 had multiply relapsed low-grade follicular lymphoma and presented October 2020 to our referral center with relapsing disease. Her clinical course and imaging studies were suggestive of transformation to diffuse large B-cell lymphoma and biopsy proved transformed disease. She was naïve to anthracyclines and therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) was planned with possible consolidation with autologous stem cell transplant. At her presentation for her first cycle of therapy her asymptomatic screening test was-positive for COVID-19 infection. She was observed for 14 days per protocol. Due to progressive worsening symptoms of her lymphoma, treatment was indicated and she received R-CHOP on 12/8/2020, 22 days after herpositive test. She presented with respiratory failure and pancytopenia on 12/17/2020, 11 days after her first cycle of R-CHOP and 31 days after her initial-positive test. She had a prolonged hospital stay including ICU admission for respiratory failure but never required mechanical ventilation. She is currently recovering and off oxygen therapy. Patient 2 presented to our center September 2020 with multiply relapsed high-grade follicular lymphoma with prior transformation to diffuse large B-cell lymphoma. In addition to transformation events, additional high risk factors included early relapse of his follicular lymphoma after therapy. He was planned to undergo salvage chemoimmunotherapy with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) and, if chemosensitive, to be consolidated with an autologous stem cell transplant. He underwent his first cycle of R-ICE October 2020 uneventfully with no significant toxicities. However, upon presentation for his second cycle of therapy, he had a-positive coronavirus test and therapy was delayed for 14 days. Given lack of symptoms and his high risk disease, it was felt in his best interest to continue therapy. He received RICE therapy 11/20/2020 and was admitted 12/27/2020 with progressive respiratory failure, 53 days after his first-positive test and 37 days after treatment. He had a prolonged ICU stay with respiratory failure and unfortunately died of acute respiratory failure 1/11/2021. Patient 3 was diagnosed with a high risk presentation of DLBCL with multiple extranodal sites of disease including the stomach and paranasal sinuses in August 2020. He was treated with 5 cycles of R-CHOP chemoimmunotherapy with intrathecal methotrexate for CNS prophylaxis. His asymptomatic screening test prior to cycle 6 was obtained on 11/24/2020 and he had no significant symptom development during his quarantine period. His sixth and final cycle of R-CHOP was administered 12/9/2020, 15 days after his-positive test. He was admitted 12/30/2020 with progressive worsening of respiratory failure and unfortunately on the evening of admission developed a large MCA stroke and was found to be in atrial fibrillation. Neurologically he improved during his hospital stay but ended up with continuous hypoxic respiratory failure throughout with several exacerbations, each of which was associated with negative work-up for alternative infectious etiologies. Given his negative work-up and serial CT scans showed progressive worsening of pulmonary fibrosis his persistent respiratory failure was attributed to progressive pulmonary fibrosis from coronavirus. He eventually died of progressive respiratory failure 1/20/2021. These cases illustrate several important principles. First, as has been noted by previous investigators, patients with significant immune suppression will shed active replicating virus over a longer period of time than patients with an intact immune system (1) . Importantly, this report suggests that prolonged shedding places them at risk of delayed symptom onset as well, especially when challenged with immunosuppressive therapy. Second, patients who have immune suppression and are on active therapy can present in a delayed fashion. In each case patients presented well beyond recommended quarantine with persistence of replicating virus and development of a worsening clinical syndrome of coronavirus infection in the context of receipt of rituximab based chemoimmunotherapy. Third, prior recent receipt of chemoimmunotherapy and subsequent infection may be less problematic than actively treating a patient who is shedding virus. In two of these cases (patients 2 and 3), the patients were on active therapy and had received rituximab based chemoimmunotherapy 19 days prior to their firstpositive test. In both of these cases COVID-19 related disease did not worsen during the 14-day period of quarantine and observation. In fact, it was not until after subsequent treatment (21 days in patient 3 and 37 days in patient 2) that these patients presented with symptoms of coronavirus related respiratory failure. These observations place the treating hematologist in a difficult position regarding how to manage patients who have an acute life-threatening hematologic malignancies requiring treatment and present with an asymptomatic positive screening test for coronavirus infection. These cases would argue for an observation period beyond 14 days but the ideal duration of observation remains unclear. Many patients regrettably do not have the luxury of a long stretch of observation and, as evidenced by the recent communication that inspired this report (1), even clearance of virus and development of antibodies may not be sufficient to prevent viral reactivation in the context of rituximab based chemoimmunotherapy. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia A Guide to Cancer Care During the COVID-19 Pandemic Centers for Disease Control and Prevention Duration of Isolation and Precautions for Adults with COVID-19 1. COVID-19 can present with delayed onset of symptoms in lymphoma patients receiving rituximab-based chemoimmunotherapy 2. In spite of delayed onset of symptoms with prolonged asymptomatic period outcomes can be particularly severe, including respiratory failure, thrombotic complications and death.